Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
International Journal of Molecular Sciences
|
January 11, 2022
Morphometry and Stiffness of Red Blood Cells-Signatures of Neurodegenerative Diseases and Aging
Velichka Strijkova-Kenderova, Svetla Todinova, Tonya Andreeva, et al.
Journal of Clinical Medicine
|
November 13, 2025
Prevalence and Associations of Poor Sleep in Patients with Relapsing-Remitting Multiple Sclerosis on Disease-Modifying Therapy
Dimitar Taskov, Sonya Ivanova, Nikolay Topalov, et al.
Movement Disorders Clinical Practice
|
March 25, 2025
Levodopa-Entacapone-Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease - Interim Analysis of the ELEGANCE Study
Daniel Weiss, Wolfgang H Jost, József Attila Szász, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
November 12, 2025
Pharmacogenetics in advanced Parkinson's disease
Jaime Kulisevsky, Pedro García-Ruíz, Tiago Fleming Outeiro, et al.
Wiener Medizinische Wochenschrift (1946)
|
August 17, 2012
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group
Franz Fazekas, Thomas Berger, Tanja Hojs Fabjan, et al.
Stroke
|
January 4, 2024
Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes
Eric E Smith, Ashkan Shoamanesh, Lizhen Xu, et al.
Journal of Palliative Medicine
|
May 30, 2020
EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis
Alessandra Solari, Andrea Giordano, Jaume Sastre-Garriga, et al.
Frontiers in Neurology
|
May 4, 2013
How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Franz Fazekas, Ovidiu Bajenaru, Thomas Berger, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
February 26, 2021
Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity
Dirk Dressler, Maria Concetta Altavista, Eckart Altenmueller, et al.
Lancet (London, England)
|
September 5, 2022
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial
Ashkan Shoamanesh, Hardi Mundl, Eric E Smith, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
International Journal of Molecular Sciences
|
January 11, 2022
Morphometry and Stiffness of Red Blood Cells-Signatures of Neurodegenerative Diseases and Aging
Velichka Strijkova-Kenderova, Svetla Todinova, Tonya Andreeva, et al.
Journal of Clinical Medicine
|
November 13, 2025
Prevalence and Associations of Poor Sleep in Patients with Relapsing-Remitting Multiple Sclerosis on Disease-Modifying Therapy
Dimitar Taskov, Sonya Ivanova, Nikolay Topalov, et al.
Movement Disorders Clinical Practice
|
March 25, 2025
Levodopa-Entacapone-Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease - Interim Analysis of the ELEGANCE Study
Daniel Weiss, Wolfgang H Jost, József Attila Szász, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
November 12, 2025
Pharmacogenetics in advanced Parkinson's disease
Jaime Kulisevsky, Pedro García-Ruíz, Tiago Fleming Outeiro, et al.
Wiener Medizinische Wochenschrift (1946)
|
August 17, 2012
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group
Franz Fazekas, Thomas Berger, Tanja Hojs Fabjan, et al.
Stroke
|
January 4, 2024
Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes
Eric E Smith, Ashkan Shoamanesh, Lizhen Xu, et al.
Journal of Palliative Medicine
|
May 30, 2020
EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis
Alessandra Solari, Andrea Giordano, Jaume Sastre-Garriga, et al.
Frontiers in Neurology
|
May 4, 2013
How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Franz Fazekas, Ovidiu Bajenaru, Thomas Berger, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
February 26, 2021
Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity
Dirk Dressler, Maria Concetta Altavista, Eckart Altenmueller, et al.
Lancet (London, England)
|
September 5, 2022
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial
Ashkan Shoamanesh, Hardi Mundl, Eric E Smith, et al.
Page
of 4